Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Hypertension
To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks
The purpose of this study is to provide sildenafil therapy to eligible adult patients with pulmonary arterial hypertension (PAH) and to the patients who completed the A1481142 study for the treatment of PAH in Poland.
- Trial name
- NCT00946114
- Testing
- sildenafil
- Where
- 2 sites in Poland
- Volunteers
- 32 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension, Randomized Controlled Trial
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH
Efficacy and safety evaluation of tolvaptan in the treatment of patients with right heart failure caused by pulmonary arterial hypertension
- Trial name
- NCT05569655
- Testing
- Tolvaptan, Furosemide
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Hypertension, Pulmonary
Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension
Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic…
- Trial name
- e-MOTION PH (NCT02536534)
- Testing
- Correlation assessment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
A Study to Evaluate GSK1325760A - a Long-Term Extension Study
The primary objective of this study is to evaluate the safety of long-term administration of GSK1325760A in patients with PAH. The secondary objectives of this study are to evaluate long-term administration of GSK1325760A on…
- Trial name
- NCT00554619
- Testing
- GSK1325760A
- Where
- 11 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice
Pulmonary arterial hypertension is a rare and serious disease that can lead to heart failure and early death despite modern treatments.
- Trial name
- REAPPRAISED (NCT07374302)
- Volunteers
- 15 people
- Sponsor
- Caio Júlio César dos Santos Fernandes
Pulmonary Arterial Hypertension
FreeFlow Percutaneous Atrial Septal Shunt for IPAH
The goal of this clinical trial is to explore the safety and efficacy of the FreeFlow percutaneous atrial septal shunt for treatment of idiopathic pulmonary arterial hypertension.
- Trial name
- FREEFLOW (NCT06605794)
- Testing
- FreeFlow percutaneous atrial septal shunt
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Pulmonary Arterial Hypertension
A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)
This study of frespaciguat in participants with Group 1 pulmonary arterial hypertension (PAH) will assess the safety, tolerability and pharmacokinetics (PK) of inhaled frespaciguat. There is no formal hypothesis to be tested.
- Trial name
- NCT03744637
- Testing
- Frespaciguat
- Where
- Moldova
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH)
Abstract This is a multi-center, open-label pharmacokinetic (PK) study examining the relationship between the steady-state plasma concentration and dose of treprostinil delivered intravenously or subcutaneously in children with…
- Trial name
- PKRemodulin (NCT02318186)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Jeffrey A. Feinstein
Pulmonary Arterial Hypertension
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
- Trial name
- NCT00477269
- Testing
- Imatinib mesylate
- Where
- 13 sites in United States, Austria and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
PAH, CTEPH
Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients
Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise.
- Trial name
- EPRQoL-PAH (NCT06973382)
- Testing
- Comprehensive Pulmonary Rehabilitation Program, Standard Pulmonary Rehabilitation
- Volunteers
- 84 people
- Sponsor
- Beijing Chao Yang Hospital
Systemic Sclerosis, Pulmonary Arterial Hypertension
Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)
A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Trial name
- DETECT (NCT00706082)
- Where
- 83 sites in United States, Austria and 18 more
- Volunteers
- 490 people
- Sponsor
- Actelion
Congenital Heart Disease, Pulmonary Arterial Hypertension
4DFlow Magnetic Resonance Imaging in Patients With Pulmonary Hypertension Associated With Congenital Heart Disease
Congenital heart disease is the most common congenital anomaly. The life expectancy of children with congenital heart disease has increased considerably in recent years.
- Trial name
- 4DFlowHTAPCC (NCT03928002)
- Testing
- 4D Flow magnetic resonance imagery, Cardiac catheterization
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Pulmonary Arterial Hypertension
Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension
Prevalence of musculoskeletal pain and its impact of quality of life and functional exercise capacity will be evaluated in patients with pulmonary arterial hypertension.
- Trial name
- NCT04808830
- Testing
- Evaluation of musculoskeletal pain prevalence, Evaluation of quality of life, Evaluation of functional exercise capacity
- Where
- Turkey (Türkiye)
- Volunteers
- 61 people
- Sponsor
- Izmir Bakircay University
Pulmonary Arterial Hypertension
A Registry for Patients Taking Uptravi
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi.
- Trial name
- SPHERE (NCT03278002)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 800 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Combination Therapy in Pulmonary Arterial Hypertension
An open label, non-comparative study design is appropriate for this Phase 4 study designed to assess whether a core therapy of bosentan, either as monotherapy or with the addition of sildenafil, enables patients with pulmonary…
- Trial name
- COMPASS 3 (NCT00433329)
- Testing
- Bosentan, Sildenafil
- Volunteers
- 100 people
- Sponsor
- Actelion
Heart Failure, Pulmonary Arterial Hypertension
Non-invasive Pulmonary Artery Prediction (ADOPTS)
A proprietary machine-learning algorithm has been developed to model continuous pulmonary artery pressure (PAP), a physiologic marker of cardiopulmonary function.
- Trial name
- ADOPTS (NCT05641675)
- Testing
- right heart catheterization
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Silverleaf Medical Sciences INC
Pulmonary Arterial Hypertension (PAH)
Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class…
- Trial name
- ATHENA (NCT07601295)
- Testing
- Tiprelestat (5 mg), Tiprelestat (10 mg)
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Stanford University
Pulmonary Arterial Hypertension
Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release (BPS-MR) tablets.
- Trial name
- NCT00990314
- Testing
- Beraprost Sodium Modified Release
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 31 people
- Sponsor
- Lung Biotechnology PBC
Interstitial Lung Disease
The Six Minute Walk Test: Influence of Instruction on Results
Two - four 6MWT performed according to ATS standards. Each walk however had specifically altered wording and coaching performed in random order to determine differences in outcomes. One walk was done in the standard ATS fashion.
- Trial name
- NCT01789996
- Testing
- alternative six minute walk test, Standard six minute walk test
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Inova Health Care Services
Pulmonary Hypertension, Pulmonary Embolism (Diagnosis)
China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization
Right heart catheterization(RHC) plays a crucial role in the diagnosis and treatment of pulmonary vascular diseases(PVD). In China, the lack of equipment and technical expertise has historically limited the implementation of RHC…
- Conditions
- Pulmonary Hypertension, Pulmonary Embolism (Diagnosis), Pulmonary Arterial Hypertension, Right Heart Catheterization
- Trial name
- CHA-RHC (NCT06954727)
- Testing
- No intervention; Observational study
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- China-Japan Friendship Hospital